EXPERT OPINION ON THERAPEUTIC TARGETS

Scope & Guideline

Empowering researchers with cutting-edge perspectives on treatment targets.

Introduction

Welcome to the EXPERT OPINION ON THERAPEUTIC TARGETS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of EXPERT OPINION ON THERAPEUTIC TARGETS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1472-8222
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1997 to 2024
AbbreviationEXPERT OPIN THER TAR / Expert Opin. Ther. Targets
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'EXPERT OPINION ON THERAPEUTIC TARGETS' is dedicated to providing insights into novel therapeutic targets across various diseases, focusing on innovative strategies that can lead to breakthroughs in treatment. This journal emphasizes the importance of understanding molecular mechanisms and pathways to identify potential targets for therapeutic intervention.
  1. Molecular Target Discovery:
    The journal emphasizes the identification and validation of new molecular targets for therapeutic intervention, exploring pathways involved in disease mechanisms.
  2. Therapeutic Strategies and Innovations:
    It covers innovative therapeutic approaches, including drug repurposing, combination therapies, and strategies to overcome drug resistance in various diseases.
  3. Translational Research:
    The focus is on bridging the gap between laboratory research and clinical applications, providing insights into how preclinical findings can be translated into effective therapies.
  4. Comprehensive Reviews and Perspectives:
    The journal publishes comprehensive reviews that synthesize current knowledge on therapeutic targets, offering perspectives on future research directions and clinical implications.
  5. Interdisciplinary Approaches:
    It encourages interdisciplinary research that integrates molecular biology, pharmacology, and clinical research to address complex health issues.
The journal has observed several emerging themes that reflect the evolving landscape of therapeutic targets and innovative treatment strategies. These trends highlight areas of increasing research interest and potential for future therapeutic advancements.
  1. Targeting the Tumor Microenvironment:
    There is a growing focus on understanding and targeting the tumor microenvironment, which plays a crucial role in cancer progression and therapeutic resistance.
  2. Immunotherapy and Immune Modulation:
    Research on immunotherapeutic approaches, including immune checkpoint inhibitors and CAR-T cell therapies, is gaining momentum as novel strategies to enhance anti-tumor immunity.
  3. Epigenetic Modulation:
    The exploration of epigenetic modifications and their potential as therapeutic targets is becoming increasingly prominent, indicating a shift towards understanding gene regulation in disease treatment.
  4. MicroRNA and Non-Coding RNAs:
    The therapeutic potential of microRNAs and other non-coding RNAs is emerging as a significant theme, highlighting their role in gene expression regulation and disease pathology.
  5. AI and Computational Drug Discovery:
    The integration of artificial intelligence and computational methods in drug discovery processes is trending, offering innovative ways to identify and validate therapeutic targets.

Declining or Waning

As the field of therapeutic targeting evolves, certain themes have shown a decreasing trend in publication frequency, indicating a shift in focus within the journal. These waning scopes may reflect changes in research priorities or advancements that have made previous approaches less relevant.
  1. Traditional Drug Discovery Approaches:
    There has been a noticeable decline in publications focusing on traditional drug discovery methods, as the field shifts towards more targeted and personalized therapeutic strategies.
  2. Single-Agent Therapies:
    Research on single-agent therapies is becoming less prominent, with a growing emphasis on combination therapies that leverage multiple mechanisms of action for improved efficacy.
  3. Basic Mechanistic Studies:
    While understanding basic mechanisms remains important, there is a waning focus on purely mechanistic studies without direct implications for therapeutic application.
  4. Lack of Novelty in Established Targets:
    As certain therapeutic targets become well-established, the novelty of research in these areas appears to be declining, leading to fewer publications on previously identified targets.
  5. Focus on Rare Diseases:
    Publications addressing rare diseases as therapeutic targets are less frequent, potentially due to a broader focus on more prevalent conditions with larger patient populations.

Similar Journals

DRUG DEVELOPMENT RESEARCH

Unveiling breakthroughs in drug development for a healthier tomorrow.
Publisher: WILEYISSN: 0272-4391Frequency: 8 issues/year

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

Future Medicinal Chemistry

Unveiling cutting-edge discoveries in medicinal chemistry.
Publisher: Newlands Press LtdISSN: 1756-8919Frequency: 24 issues/year

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

Drug Target Insights

Exploring the Frontiers of Medicinal Biochemistry.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

TRENDS IN PHARMACOLOGICAL SCIENCES

Bridging Knowledge and Practice in Pharmacological Sciences
Publisher: CELL PRESSISSN: 0165-6147Frequency: 12 issues/year

TRENDS IN PHARMACOLOGICAL SCIENCES, an esteemed journal published by CELL PRESS, is a leading platform in the field of pharmacology and toxicology, with an impressive history since its inception in 1979. With an impact factor that places it in the top quartile category (Q1) for both pharmacology and toxicology as of 2023, it is recognized for disseminating high-quality, peer-reviewed research that shapes the future of these disciplines. The journal is indexed with a robust standing in Scopus rankings, positioned at rank #2 in Toxicology and #6 in Pharmacology, both boasting an extraordinary percentile of 98. Researchers, professionals, and students benefit from its comprehensive coverage, which spans cutting-edge advancements, review articles, and significant trends in drug development and toxicity assessment. While the journal does not currently offer open access options, it remains a vital resource for the academic community, ensuring critical insights into the complexities of pharmacological sciences are readily available to enhance research and practice.

Current Molecular Pharmacology

Connecting Researchers to Cutting-edge Pharmacological Insights
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4672Frequency: 7 issues/year

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

MEDICINAL RESEARCH REVIEWS

Advancing the Frontiers of Therapeutic Innovation
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

JOURNAL OF PHARMACY AND PHARMACOLOGY

Connecting researchers to the pulse of pharmaceutical innovation.
Publisher: OXFORD UNIV PRESSISSN: 0022-3573Frequency: 12 issues/year

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.

Drug Research

Advancing the Frontiers of Pharmacology
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

CURRENT CANCER DRUG TARGETS

Advancing targeted therapies for a cancer-free tomorrow.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

Biochemistry Research International

Unlocking the secrets of molecular biology, one study at a time.
Publisher: HINDAWI LTDISSN: 2090-2247Frequency: 1 issue/year

Biochemistry Research International is a prominent and dynamic journal published by Hindawi Ltd, dedicated to advancing knowledge in the field of biochemistry. With its Open Access model established since 2010, the journal provides unrestricted access to high-quality research, thereby fostering global communication among researchers and professionals. Operating out of the United States, Biochemistry Research International serves as a vital platform for disseminating cutting-edge findings in biochemistry and molecular biology, holding a respectable Q2 ranking in its category as of 2023. The journal's scope encompasses a wide array of topics including but not limited to biochemical processes, genetic engineering, and molecular interactions, making it an essential resource for students and seasoned researchers alike. With an impact factor reflective of its significance in the academic community, Biochemistry Research International continues to play an integral role in shaping the future of biochemistry research.